Cargando…

Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada

INTRODUCTION: Several jurisdictions have adopted a more conservative approach to anemia in patients receiving dialysis amid safety concerns from target hemoglobin studies. It is largely unknown if this has contributed to a change in clinical outcomes. METHODS: A national registry was used to identif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canney, Mark, Birks, Peter, Shao, Selena, Parfrey, Patrick, Djurdjev, Ognjenka, Levin, Adeera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071619/ https://www.ncbi.nlm.nih.gov/pubmed/33912762 http://dx.doi.org/10.1016/j.ekir.2020.12.022

Ejemplares similares

Effectiveness of Latent TB Screening and Treatment in People Initiating Dialysis in British Columbia, Canada
por: Romanowski, Kamila, et al.
Publicado: (2020)

Prescription Pattern of Cation Exchange Resins and Their Efficacy in Treating Chronic Hyperkalemia Among Patients With Chronic Kidney Diseases: Findings From a Population-Based Analysis in British Columbia, Canada
por: Atiquzzaman, Mohammad, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness in patients with non–dialysis-dependent chronic kidney diseases: findings from a population-based observational study from British Columbia, Canada
por: Atiquzzaman, Mohammad, et al.
Publicado: (2022)

Chronic kidney disease and support provided by home care services: a systematic review
por: Aydede, Sema K, et al.
Publicado: (2014)

Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT)
por: Levin, Adeera, et al.
Publicado: (2013)

Systematic Evaluation of a Provincial Initiative to Improve Transition to Home Dialysis Therapies
por: Wang, Alice, et al.
Publicado: (2020)

The Variability of Estimated Glomerular Filtration Rate Decline in Alport Syndrome
por: Langsford, David, et al.
Publicado: (2016)

Adverse changes in key chronic kidney disease care outcome metrics since the onset of the COVID-19 pandemic: experience from an established provincial renal program
por: Bevilacqua, Micheli, et al.
Publicado: (2022)

An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework
por: Barbour, Sean, et al.
Publicado: (2013)

Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis
por: Khan, Irfan, et al.
Publicado: (2011)

COVID-19 Vaccine Effectiveness Among Patients With Maintenance Dialysis; Observations From Population Level Cohort Studies in 2 Large Canadian Provinces
por: Atiquzzaman, Mohammad, et al.
Publicado: (2023)

Time to revisit the problem of CIN? The low incidence of acute kidney injury with and without contrast in hospitalized patients: an observational cohort study
por: Hemmett, Juliya, et al.
Publicado: (2015)

Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study
por: Hutton, Holly L., et al.
Publicado: (2017)

A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients
por: Levin, Adeera, et al.
Publicado: (2014)

Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada
por: Ha, Jeffrey T., et al.
Publicado: (2023)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Maintaining the Uptake of Peritoneal Dialysis During the COVID-19 Pandemic: A Research Letter
por: Canney, Mark, et al.
Publicado: (2021)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
por: Suttorp, Marit M., et al.
Publicado: (2013)

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
por: Pirker, Robert, et al.
Publicado: (2012)

External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for end-stage kidney disease
por: Forzley, Brian, et al.
Publicado: (2017)

Predicting kidney failure risk after acute kidney injury among people receiving nephrology clinic care
por: Sawhney, Simon, et al.
Publicado: (2018)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis
por: Bonafont, Xavier, et al.
Publicado: (2009)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

No TREATment with Darbepoetin Dosed to Hemoglobin 13 Grams per Deciliter in Type 2 Diabetes with Pre-Dialysis Chronic Kidney Disease - Safety Warnings for Erythropoiesis-Stimulating Agents
por: Curtiss, Frederic R.
Publicado: (2009)

Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study
por: Castillo, Nieves, et al.
Publicado: (2012)

Use of Erythropoiesis-Stimulating Agents Among Chemotherapy Patients With Hemoglobin Exceeding 12 Grams Per Deciliter
por: Nordstrom, Beth L., et al.
Publicado: (2008)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status
por: Toblli, Jorge Eduardo, et al.
Publicado: (2015)

Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease
por: El Hoss, Sara, et al.
Publicado: (2020)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

A Provincial Survey of the Contemporary Management of Autosomal Dominant Polycystic Kidney Disease
por: Yi, Tae Won, et al.
Publicado: (2020)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Perceptions of prognostic risks in chronic kidney disease: a national survey
por: Chiu, Helen H. L., et al.
Publicado: (2015)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

The British Columbia Nephrologists’ Access Study (BCNAS) – a prospective, health services interventional study to develop waiting time benchmarks and reduce wait times for out-patient nephrology consultations
por: Schachter, Michael E, et al.
Publicado: (2013)

THE RELATIONSHIP BETWEEN RNA SYNTHESIS AND HEMOGLOBIN SYNTHESIS IN AMPHIBIAN ERYTHROPOIESIS : Cytochemical Evidence
por: Grasso, Joseph A., et al.
Publicado: (1966)

Cannot write session to /tmp/vufind_sessions/sess_dpuk749vgjetkpqree0erfre64